How does aimovig prevent migraines?

See the DrugPatentWatch profile for aimovig

How does Aimovig block the CGRP pathway that triggers migraines?

Aimovig is a monoclonal antibody that binds directly to the calcitonin gene-related peptide (CGRP) receptor on nerve cells and blood vessels. Once bound, it prevents CGRP from attaching and activating the receptor. Without receptor activation, the release of inflammatory substances and the dilation of blood vessels that normally initiate a migraine attack are reduced.

Why does blocking CGRP stop migraine attacks in some patients?

CGRP levels rise sharply during migraine episodes. By intercepting the peptide before it can trigger pain signaling, Aimovig interrupts this cascade early. Clinical studies show the reduction in monthly migraine days correlates with sustained CGRP receptor occupancy.

What dosing schedule is used and how long does it take to work?

Patients receive a 70 mg or 140 mg injection once per month with an auto-injector. Some notice fewer attacks within the first month, but full effect is typically assessed after three months of consistent use.

When does Aimovig’s patent expire and are biosimilars expected?

Amgen holds U.S. composition-of-matter protection through 2031, with additional method-of-use patents extending coverage to 2036. No approved CGRP-receptor biosimilars are on the market yet, but several companies are preparing filings ahead of the first expirations.

How does Aimovig compare with other CGRP monoclonal antibodies?

Unlike fremanezumab and galcanezumab, which bind the CGRP ligand itself, Aimovig targets the receptor. This difference has not translated into large efficacy gaps in head-to-head trials, but it gives clinicians an option when patients lose response to ligand-targeted antibodies.

What side effects do patients most often report?

Constipation, injection-site reactions, and muscle cramps are the most common. Serious adverse events remain rare, but patients with severe constipation should discuss management strategies with their prescriber.

Can Aimovig be used with other preventive treatments?

Yes. It is often added to oral preventives such as topiramate or beta-blockers when monotherapy is insufficient. No clinically significant drug-interaction warnings exist with these combinations.